Levodopa: Is toxicity a myth?

Neurology

Volumn 57, Issue 10 SUPPL. 3, 2001, Pages 858-863

  Agid, Y ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0039783970     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Fahn S. Is levodopa toxic? Neurology 1996;47(suppl 3):S184-S195.
2. Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990;26:428-435.
3. Pardo B, Mena MA, Fahn S, De Yébenes JG. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Disord 1993;8:278-284.
4. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-dopa on mesencephalic cell cultures. J Neurochem 1993; 61:1470-1478.
5. Pardo B, Mena MA, Casarejos MJ, Paíno CL, de Yébenes JG. Toxic effects of L-dopa on mesencephalic cell cultures: protection with antioxidants. Brain Res 1995;682:133-143.
6. Ziv I, Melamed E, Nardin N, et al. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994;170:136-140.
7. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures. J Neurochem 1997;69:1398-1408.
8. Pelton EW, Kimelberg HK, Shipherd SV, Bourke RS. Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture. Life Sci 1981;28:1655-1663.
9. Desagher S, Glowinski J, Premont J. Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 1996;16: 2553-2562.
10. Mena MA, Casarejos MJ, Carazo A, Paino CL, de Yébenes JG. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-dopa toxicity. Neuroreport 1996;7:441-445.
11. Han SK, Mytilineou C, Cohen G. L-dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996;66:501-510.
12. Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Pharmacokinet 1987;13:141-178.
13. Yahr MD. Evaluation of long-term therapy in Parkinson's disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, eds. Advances in parkinsonism. Basel: Editions Roche, 1976:444-455.
14. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Multi-center study of Parkinson's mortality with early versus late dopa treatment. Ann Neurol 1987;22:8-12.
15. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990;40:265-269.
16. Quinn N, Parkes D, Janota I, Marsden CD. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
17. Rajput AH, Fenton ME, Birdi S, Macaulay R. Is levodopa toxic to human substantia nigra? Mov Disord 1997;5:634-638.
18. Yahr MD, Wolf A, Antunes JL, Miyoshi K, Duffy P. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1972;22(suppl):56-71.
19. Cotzias GC, Miller ST, Tang LC, Papavasiliou PS. Levodopa, fertility, and longevity. Science 1977;196:549-551.
20. Hefti F, Melamed E, Bhawan J, Wurtman RJ. Long-term administration of levodopa does not damage dopaminergic neurons in the mouse. Neurology 1981;31:1194-1195.
21. Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-dopa and carbidopa chronically. J Neurochem 1984;43:990-993.
22. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993;8:129-133.
23. Dziewczapolski G, Murer G, Agid Y, Gershanik O, Raisman-Vozari R. Absence of neurotoxicity of chronic L-dopa treatment in 6-hydroxydopamine lesioned rats. Neuroreport 1997;8:975-979.
24. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 1996;93:1956-1961.
25. Steece-Collier K, Yurek DM, Collier TJ, Junn FS, Sladek JR. The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdrawal of chronic dosing. Brain Res 1995;676: 404-408.
26. Murer G, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998 (in press).
27. Bonnet A-M, Loria Y, Saint-Hilaire M-H, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37:1539-1542.
28. Agid Y, Ruberg M, Raisman R, Hirsch E, Javoy-Agid F. The biochemistry of Parkinson's disease. In: Stern GM, ed. Parkinson's disease. London: Chapman Hall, 1990:99-125.
29. Marsden CD. On-off phenomena in Parkinson's disease. In: Rinne UK, Klinger M, Stamm G, eds. Parkinson's disease-current progress, problems and management. Amsterdam: Elsevier, North Holland Biomedical Press, 1980:241-254.
30. Agid Y, Bonnet AM, Ruberg M, Javoy-Agid F. Pathophysiology of levodopa-induced abnormal involuntary movements. In: Casey D, Chase TN, Christensen V, Gerlach J, eds. Dyskinesia. Research and treatment. Berlin: Springer-Verlag, 1985: 145-159.
31. Melamed E, Hefti F, Wurtman RJ. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model. Isr J Med Sci 1982;18: 159-163.
32. Graybiel AN, Hirsch EC, Agid Y. The nigrostriatal system in Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Advances in Neurology, vol. 53: Parkinson's disease: anatomy, pathology and therapy. New York: Raven Press, 1990:17-29.
33. Mouradian MM, Chase TN. Improved dopaminergic therapy in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement disorders. Oxford: Butterworth-Heinemann, 1994:181-199.
34. Obeso JA, Grandas F, Herrero MT, Horowski R. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. Eur J Neurosci 1994;6:889-897.
35. Lesser RP, Fahn S, Snider SR, Cote LJ, Isgreen WP, Barret RE. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29:1253-1260.
36. Blin J, Bonnet A-M, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416.
37. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384.
38. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
39. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part II. Ann Neurol 1988;24: 372-378.
40. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
41. Wichmann T, De Long MR. Pathophysiology of parkinsonian motor abnormalities. In: Narabayashi H, Nagatsu T, Yanagisawa N, Mizuno Y, eds. Advances in neurology. New York: Raven Press, 1993:53-61.
42. Vila M, Herrero MT, Levy R, et al. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and non-human primates: an in situ hybridization study of cytochrome oxidase subunit 1 mRNA. J Neurosci 1997;17:765-773.
43. Harden DG, Grace AA. Activation of dopamine cell firing by repeated L-dopa administration to dopamine-deleted rats: its potential role in mediating the therapeutic response to L-dopa treatment. J Neurosci 1995;15:6157-6166.
44. Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. Lancet 1982;ii:412-415.
45. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859.
46. Bordet R, Ridray S, Carboni S, Diaz J, Sokoloff P, Schwartz JC. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc Natl Acad Sci USA 1997;94:3363-3367.
47. Hurley MJ, Stubbs CM, Jenner P, Marsden CD. D3 receptor expression within the basal ganglia is not affected by Parkinson's disease. Neurosci Lett 1996;214:75-78.
48. Filion M, Tremblay L, Bédard PJ. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res 1988;444: 165-176.
49. Anglade P, Mouatt-Prigent A, Agid Y, Hirsch EC. Synaptic plasticity in the caudate nucleus of patients with Parkinson's disease. Neurodegeneration 1996;5:121-128.
50. Koller WC, Weiner WJ, Perlik S, Nausieda PA, Goetz CG, Klawans HL. Complications of chronic levodopa therapy: long term efficacy of drug holiday. Neurology 1981;31:473-476.